Xeris Biopharma Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 total revenue was $107.2 million, up 44% year over year and 16% sequentially; net product revenue was $106.3 million, up 43% or $32.2 million year over year.
- Recorilev net revenue was $71.5 million, up 93% or $34.6 million year over year and $14.8 million or 26% sequentially, with record referrals and new patient starts.
- Gvoke net revenue was $21.7 million, compared with $25.2 million in the third quarter of 2025; prescription demand grew 5% year over year, offset by a $4 million one-time gross-to-net adjustment in the Medicaid channel.
- Kavaeus generated $13 million in net revenue, up 9% year over year and marking its fourth consecutive quarter of year-over-year growth.
- Gross margin was 88%, compared with 85% in the prior-year period, reflecting favorable product mix; adjusted EBITDA was $30.8 million, up $13.3 million or 77% year over year, and net income was $11.3 million, compared with $0.6 million.
- Through the first nine months of 2026, total revenue grew 37% year over year and adjusted EBITDA increased from $34 million to $65 million.
- Third-quarter R&D expenses were $11.1 million, up $3.6 million year over year, and SG&A expenses were $64.1 million, up $17.6 million, primarily due to higher personnel-related expenses.
- The company reported a new Kavaeus patent issued October 13, with protection through at least 2043, and a third U.S. patent for XP-8121 issued October 6, with patent protection extending to October 2043.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to Xeris Biopharma Third Quarter 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. Those on the webcast can submit a text question by clicking the Q&A button on the bottom right corner of the screen. I will now hand the conference over to Cristi Barnett, Vice President of Investor Relations. Please go ahead. Thank you, Bella.
Good morning, everyone, and welcome to Xeris Biopharma's Third Quarter 2026 Financial Results Conference Call. Earlier this morning, we issued a press release detailing our third quarter 2026 financial and operating results. This press release can be found on our website at xerispharma.com. Joining me on today's call are John Shannon, our Chairman and Chief Executive Officer, and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we will open the call for your questions. Before we begin, I'd like to remind you that today's discussion will include forward-looking statements regarding Xeris' future expectations, plans, strategies, objectives, and financial performance, including our full year 2026 financial guidance and our 2030 outlook. These forward-looking statements are based on management's current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC, including our most recent annual report on Form 10-K and our subsequent filings with the SEC, as well as the forward-looking statements disclaimer in our earnings release. In addition, during today's call, we will reference certain financial measures that are presented on a non-GAAP basis. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included in our earnings release. Before I turn it over to John, I'd like to briefly introduce myself. I'm Cristi Barnett, and I recently joined Xeris to lead investor relations following Allison Wey's retirement.
Some of you may know me from my previous companies, and for those who I haven't yet met, I look forward to connecting and working with you. We will miss Allison here at Xeris, and I'm pleased to carry the investor relations baton forward. I look forward to an open dialogue and to keeping you informed about Xeris' progress. With that, I'll turn it over to John.
Thank you, Kristi, and welcome to Xeris. We are happy to have you on the team. Good morning, everyone. I am pleased to report that Xeris had a spectacular third quarter, and we now see our company on a new growth curve, one that is both accelerating our near-term financial outlook and redefining what we believe is possible for this company. Importantly, this new trajectory reflects expected growth from the entire enterprise, Recorlev, Gvoke, and KEVEYIS. Total revenue grew more than 44% year-over-year, led by Recorlev, where the expanded commercial team moved from build to yield and delivered record referrals and new patient starts. Gvoke delivered a better-than-expected back-to-school prescription lift, and prescription demand is back in solid growth mode. KEVEYIS continued its steady, high-value contribution. Now, with a recently issued patent, we intend to intensify our efforts to identify more patients that could benefit from therapy.
Results like these reflect years of disciplined execution and focused innovation, and they reflect who Xeris has become, a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines. We convert innovation into durable revenue growth that continues to compound. This is our model, and this quarter is further evidence it is working. Given the strong momentum across Recorlev, Gvoke, and KEVEYIS, we are raising our full-year total revenue guidance to $395 million-$405 million, and we see this new trajectory extending well beyond 2026. We are now on a path to reach more than $1 billion in total revenue in 2030, up from our prior outlook of $750 million, which we first disclosed back in June of 2025.
We also now see Recorlev on a path to $1 billion in annual net revenue three to four years sooner than we previously projected. These are meaningful increases to our expectations, grounded in the progress we are making right now. We are building on a stronger foundation and creating a larger opportunity than we previously envisioned. Beyond 2030, we see significant incremental opportunity with our late-stage pipeline asset, XP-8121. With that, let's turn to our brands, beginning with Recorlev. Recorlev continues to demonstrate exceptional momentum, and in the third quarter, it shifted into a higher gear. Net revenue increased to more than $71 million, an increase of 93% or $35 million year-over-year.
Quarter after quarter, RECORLEV has delivered exceptional growth that speaks to the execution by our commercial team, and most importantly, the deepening confidence prescribers have in RECORLEV as their treatment of choice for endogenous Cushing syndrome. We believe RECORLEV should be the standard of care, and we intend to drive it there. On our last call, we said the benefits of our January commercial expansion would begin to show up in the third quarter, and they have. Our expanded team is trained, deployed, and productive. We had a record number of new referrals, new patient starts in the quarter. The team's productivity is now running ahead of our expectations and is the key driver behind the upward revision of our 2026 and our 2030 outlooks. Also, favorable dynamics should continue to fuel an expansion of the hypercortisolism market.
Just last month, the American Diabetes Association and the European Association for the Study of Diabetes issued updated guidance on the role of hypercortisolism in difficult-to-control type 2 diabetes and included recommendations for additional screening. Recorlev's growth continues to benefit from expanded screening that is helping clinicians to identify more patients. Our medical affairs team recently convened our fourth annual Cortisol Summit Scientific Advisory Board, bringing together leading pituitary and adrenal experts to advance research priorities and clinical management of Cushing syndrome. At the Cardiometabolic Health Congress, we presented real-world evidence illustrating the systemic benefits of cortisol normalization in a patient with uncontrolled type 2 diabetes, hypertension, and multiple other comorbidities, further underscoring the significant and growing opportunity ahead for Recorlev. Now turning to Gvoke. Gvoke delivered better-than-expected back-to-school prescription growth in the third quarter, with total prescriptions growing 20% over Q2 and 5% year-over-year.
We continue to build the evidence base for ready-to-use glucagon. At the recent Breakthrough T1D Clinical and Research Congress, we presented real-world data on the gap between healthcare provider awareness of prescribing guidelines for ready-to-use glucagon and actual prescribing practices. That gap is precisely the opportunity in front of us. Of the roughly 15 million people with diabetes who should have a potentially life-saving product like Gvoke, only about 1 million do. Closing that gap remains an important opportunity for us and a meaningful way to improve patient lives. I am extremely proud of the team's work here. We began to see Gvoke demand generation build in the second quarter, accelerate in Q3, and carry right into Q4. Our prescription growth reflects improving underlying demand, giving us confidence that Gvoke is on a sustainable growth trajectory.
Despite a one-time gross-to-net adjustment in the period, which Steve will walk through shortly, we are confident that Gvoke is now back to contributing steady unit and dollar growth in the future. Finally, Keveyis. Keveyis delivered more than $13 million in net revenue, demonstrating the brand's continued strength as a meaningful growth contributor to our business going forward. Maintaining patients on therapy remains the ultimate proof point, and our results continue to reflect both the clinical value of Keveyis and the patient-centric support infrastructure we have built for the PPP community. Last month, our steadfast multi-year effort to secure important IP protection for Keveyis was realized. On October 13th, the U.S. Patent Office issued a new patent covering Keveyis with protection through at least 2043.
With this patent now issued and having demonstrated such remarkable durability, we are investing incrementally in Keveyis and the PPP community to identify and support even more patients. Turning to our pipeline, specifically our late-stage XP-8121 program. In September, we hosted our XP-8121 program overview, providing a detailed look at our comprehensive clinical development strategy, including Cornerstone, our pivotal phase III study designed for regulatory approval, Capstone, our pediatric study, and Touchstone, our study in patients with inconsistent control despite oral therapy. We remain on track to initiate Cornerstone by year-end, with top-line data expected in late 2028 and potential approval and launch in 2030. Since our September update, we have continued to advance all work required to initiate our Cornerstone phase III study. We are especially encouraged by our startup study activities and the enthusiasm of sites to participate in Cornerstone.
In parallel, our real-world evidence program continues to advance. This week, at the American Thyroid Association annual meeting in Philadelphia, we are presenting real-world evidence on biochemical control among patients treated with oral levothyroxine. These efforts are helping us deepen our understanding of the treatment challenges in hypothyroidism and further inform the opportunity for XP-8121. We also continue to strengthen the intellectual property supporting XP-8121. on October 6th, we were granted our third U.S. patent covering the program, reinforcing XP-8121's patent protection, which extends to October 2043. This patent represents another important milestone in building the long-term foundation for XP-8121. We believe XP-8121 has the potential to address persistent challenges faced by patients and healthcare providers in managing hypothyroidism.
With peak sales potential of $1 billion-$3 billion, XP-8121 represents a significant long-term commercial opportunity and has the potential to become foundational to Xeris' future growth and long-term value creation. Before I turn the call over to Steve, let me briefly recap the progress we are making against the three critical priorities we outlined in March and remain focused on. First, driving rapid revenue growth. Through the first nine months of the year, total revenue grew 37% year over year. Based on that performance, we now expect full-year revenue of $395 million-$405 million, or growth of 37% at the midpoint. Second, advancing our pipeline. We laid out a comprehensive XP-8121 development program in September and remain on track to initiate our pivotal phase III Cornerstone study by year-end. We also secured a third U.S. patent. And third, executing with discipline.
Adjusted EBITDA grew 77% year over year, even as we continued to make strategic investments for growth. Our record commercial momentum and disciplined execution against our strategic priorities positions us well for the future, and I am incredibly proud of the company we have built and confident in our ability to deliver long-term value for shareholders through the 2030s and beyond. And with that, I'll turn the call over to Steve.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
